share_log

Aurora Cannabis | 6-K: Report of foreign private issuer (related to financial reporting)

Aurora Cannabis | 6-K: Report of foreign private issuer (related to financial reporting)

极光大麻 | 6-K：外国发行人报告（业绩相关）
美股SEC公告 ·  2024/11/06 04:37

Moomoo AI 已提取核心信息

Aurora Cannabis reported strong Q2 fiscal 2025 results with total revenue reaching $81.1 million, up 29% YoY, driven by 41% growth in global medical cannabis and 21% growth in plant propagation. The company achieved record adjusted EBITDA of $10.1 million, a 210% increase YoY. Medical cannabis revenue grew to $61.3 million, with international revenue surpassing Canadian medical revenue for the first time at $35 million.The company maintained robust financial health with approximately $152 million in cash and a debt-free cannabis business. Adjusted gross margin before fair value adjustments was 54%, up from 51% in the prior year, while medical cannabis gross margins reached 68%. The company's strategic focus on high-margin medical markets, particularly in Australia, Germany, Poland, and the UK, contributed to the strong performance.Looking ahead to Q3 2025, Aurora expects continued strong revenue and margins in its global medical cannabis business, supported by growth in Europe and Australia. The company remains committed to achieving positive free cash flow by December 31, 2024, while maintaining operational excellence and strategic growth initiatives.
Aurora Cannabis reported strong Q2 fiscal 2025 results with total revenue reaching $81.1 million, up 29% YoY, driven by 41% growth in global medical cannabis and 21% growth in plant propagation. The company achieved record adjusted EBITDA of $10.1 million, a 210% increase YoY. Medical cannabis revenue grew to $61.3 million, with international revenue surpassing Canadian medical revenue for the first time at $35 million.The company maintained robust financial health with approximately $152 million in cash and a debt-free cannabis business. Adjusted gross margin before fair value adjustments was 54%, up from 51% in the prior year, while medical cannabis gross margins reached 68%. The company's strategic focus on high-margin medical markets, particularly in Australia, Germany, Poland, and the UK, contributed to the strong performance.Looking ahead to Q3 2025, Aurora expects continued strong revenue and margins in its global medical cannabis business, supported by growth in Europe and Australia. The company remains committed to achieving positive free cash flow by December 31, 2024, while maintaining operational excellence and strategic growth initiatives.
极光大麻公布了2025财年第二季度强劲的业绩，总营业收入达到8110万，同比增长29%，主要得益于全球医疗大麻增长41%以及植物繁殖增长21%。公司实现了创纪录的调整后EBITDA为1010万，同比增长210%。医疗大麻的营业收入增长至6130万，国际营业收入首次超过加拿大医疗营业收入，达到3500万。公司保持了强劲的财务健康状态，现金约为15200万，且大麻业务无债务。在公允价值调整前的调整毛利率为54%，高于上一年的51%，而医疗大麻的毛利率达到68%。公司在高毛利医疗市场的战略重点，尤其是在澳洲、德国、波兰和英国，促进了强劲的业绩。展望2025年第三季度，极光大麻预计其全球医疗大麻业务将继续保持强劲的营业收入和毛利，得益于欧洲和澳洲的增长。公司承诺在2024年12月31日之前实现积极的自由现金流，同时保持运营卓越和战略增长计划。
极光大麻公布了2025财年第二季度强劲的业绩，总营业收入达到8110万，同比增长29%，主要得益于全球医疗大麻增长41%以及植物繁殖增长21%。公司实现了创纪录的调整后EBITDA为1010万，同比增长210%。医疗大麻的营业收入增长至6130万，国际营业收入首次超过加拿大医疗营业收入，达到3500万。公司保持了强劲的财务健康状态，现金约为15200万，且大麻业务无债务。在公允价值调整前的调整毛利率为54%，高于上一年的51%，而医疗大麻的毛利率达到68%。公司在高毛利医疗市场的战略重点，尤其是在澳洲、德国、波兰和英国，促进了强劲的业绩。展望2025年第三季度，极光大麻预计其全球医疗大麻业务将继续保持强劲的营业收入和毛利，得益于欧洲和澳洲的增长。公司承诺在2024年12月31日之前实现积极的自由现金流，同时保持运营卓越和战略增长计划。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Citius Oncology
    CTOR
    -- 0.930
    脑再生科技
    RGC
    -- 31.880
    正业生物
    ZYBT
    -- 5.380
    Emergent BioSolutions
    EBS
    -- 4.860
    Ironwood医药
    IRWD
    -- 1.470
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    FOMC维持利率但不确定性高企：美股后市走向如何？
    🎙️讨论 1. 美联储强调政策路径存在“高度不确定性”，你更关注利率预期变化还是经济数据对市场的短期影响？ 2. 若核心通胀维持高位，哪类板块更具交易机会——防御型股票还是科技成长股？ 展开
    联邦公开市场委员会新闻发布会，2025年3月19日